Effects Of Olanzapine In Patients Research Articles

Metabolic Side Effects of Olanzapine in Patients With Psychotic Disorders in Oman: A Retrospective Cohort Study.

We evaluated the impact of olanzapine on metabolic changes in patients with psychotic disorders. This was a retrospective cohort study involving patients prescribed olanzapine and attending Sultan Qaboos University Hospital (Muscat, Oman). Patients were followed up retrospectively from March 2006 until April 2021. Cardiovascular treatment targets were evaluated as per the 2019 European Society of Cardiology guidelines. We enrolled 253 patients (mean age: 40±17 years). Olanzapine monotherapy was associated with increased body weight (+8kg; 95% confidence interval (CI): 6-9; P < .001), body mass index (+3kg/m2; 95% CI: 2-4; P < .001), total cholesterol (+.4mmol/L; 95% CI: .3-.5; P < .001), low-density lipoprotein cholesterol (LDL-C) (+.3mmol/L; 95% CI: .1-.4; P < .001), fasting triglycerides (+.2mmol/L; 95% CI: .1-.3; P<.001), fasting glucose (+.6mmol/L; 95% CI: .4-.7; P< .001), HbA1c (+.3%; 95% CI: .2-.4; P < .001), systolic blood pressure (BP) (+9 mmHg; 95% CI: 6-12; P < .001) and diastolic BP (+4 mmHg; 95% CI: 2-6; P < .001) levels. Cardiovascular therapeutic goals were attained in 38% (n = 97), 61% (n = 154), 71% (n = 180), and 59% (n = 150) for LDL-C, non-high-density lipoprotein cholesterol, triglycerides, and BP, respectively. Olanzapine was associated with adverse metabolic changes. Therefore, many patients were not at their target cardiovascular treatment goals.

Cigarette smoking and heavy coffee drinking affect therapeutic response to olanzapine

Introduction/Objective. Considering relatively complex pharmacokinetic profile of olanzapine, it is expected that certain medications and some compounds, found in food and drink, can induce or inhibit its metabolism. The aim of our study was to investigate the influence of cigarette smoking and heavy coffee consumption on the clinical response to olanzapine. Methods. The phase IV, open-labeled, four-week-long prospective clinical trial included 108 adult patients diagnosed with schizophrenia. According to cigarette smoking (n = 52) and coffee drinking (n = 55), four subgroups were defined: non-smokers, non-heavy coffee consumers (group 1), non-smokers, heavy coffee consumers (group 2), smokers, non-heavy coffee consumers (group 3) and smokers and heavy coffee consumers (group 4). Positive and Negative Syndrome Scale (PANSS) and Global Assessment of Functioning (GAF) scales were used for therapeutic response evaluation. Results. Baseline and final GAF scores were 33.3 ? 5.0 and 61.5 ? 9.6, respectively, and PANSS scores were 100.7 ? 3.9 and 85.5 ? 5.4, respectively. The changes of GAF and PANSS scores from the baseline to the study end were 115.1 ? 35.7 and -19.6 ? 3.1, respectively (group 1), 91.1 ? 30.8 and -15.3 ? 2.9, respectively (group 2), 76.1 ? 29.8 and -13.4 ? 4.4, respectively (group 3), and 64.7 ? 29.3 and -11.3 ? 3.22, respectively (group 4), making significant subgroup differences for both scale scores (p &lt; 0.001). Cigarette smoking and heavy coffee drinking significantly and independently diminished improvement in both GAF and PANSS total score (p &lt; 0.001). Changes of body mass index from the baseline significantly influenced the change of PANSS total score only (p = n.s.), in a negative direction (r = -0.454, p &lt; 0.001). Conclusion. Smoking and heavy coffee drinking influenced effects of olanzapine in patients with schizophrenia treated in routine practice.

P03-322 - Effectiveness of olanzapine in patients with schizofrenia

IntroductionOlanzapine is a novel antipsychotic agent. It has a pleotrophic pharmacology and affects dopaminergic, serotonergic, muscarinic and adrenergic activities. The therapeutic advantage of recent antipsychotics (so-called atypical antipsychotics) has been attributed to alpha-2 adrenergic antagonist effects.ObjectiveThe aim of this study was to evaluated effectiveness of Olanzapine in patients with schizophrenia.MethodsStudy was designed for 8-week, observational study. 40 patients, both genders, aged 20-65 years, with diagnosed various types of schizophrenia were enrolled in the study as outpatient and inpatient setting. The patients had to have a total score ≥40 on Positive and Negative scale - two parts of the Positive and Negative Syndrome Scale (PANSS). The efficacy parameter was the percent of score difference between baseline and week 8 of therapy on two above-mentioned PANSS subscales. The difference was considered as significant improvement if decrease from the baseline was 20% or more.ResultsAll 40 enrolled patients completed the study. After the 8 weeks of treatment, 32/40 patients (80%) had clinically significant improvement of 20% or more decreased total PANSS score (Positive and Negative subscale). In 8/40 patients (20%) clinical improvement was also reported with &lt; 20% decreased total PANSS score.ConclusionsIn this observational study olanzapine appears to be very good effectiveness in patients with schizophrenia.

Sleep-related memory consolidation and the effects of olanzapine in patients with schizophrenia

Cognitive impairments such as memory deficits and sleep disturbances are common clinical features of schizophrenia. We recently described a correlation of visuospatial memory impairments and a decrease in the amount of slow wave sleep (Göder et al., J Psychiatr Res 2004). The aim of this study was to test the effects of the second generation atypical antipsychotic agent olanzapine on sleep and sleep-related memory consolidation. We studied 26 patients with schizophrenia on stable antipsychotic medication with amisulpride (age range 19–44 years, seven women). Immediately before polysomnography and the morning after we performed neuropsychological tasks including verbal and visual declarative memory tests. Before the third night in the sleep laboratory patients received either olanzapine or a placebo. We could confirm our previous results of a significant positive association of slow wave sleep and declarative memory performance in patients with schizophrenia. Olanzapine caused a significant increase in the amount of slow wave sleep, but not an improvement in sleep-related memory consolidation. We suggest, that other untoward effects of olanzapine neutralized putative positive effects on memory performance.

The molecular pharmacogenetic study on clinical response and adverse effect of olanzapine in patients with schizophrenia

The molecular pharmacogenetic study on clinical response and adverse effect of olanzapine in patients with schizophrenia

Olanzapine versus propranolol in essential tremor

Purpose In this study, we evaluated the anti-tremor effect of olanzapine in patients with essential tremor (ET). Material and methods Thirty-eight patients with ET affecting upper limbs underwent a randomized, crossover study with olanzapine (20 mg/day) and propranolol (120 mg/day). Evaluation (baseline and 1 month after each drug) was done by using the tremor clinical rating scale and a self-reported disability scale. Results We did not find statistical difference in all tremor parameters before treatment in two groups. Both drugs improved essential tremor parameters. However, olanzapine significantly improved all tremor parameters except hygiene as compared to propronalol. Conclusion These results suggest that olanzapine might be efficacious for essential tremor. Further clinical trials are indicated to establish the efficacy of olanzapine in patients with ET.